HIGH-DOSE CYTARABINE FOR THE TREATMENT OF BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

被引：0
|
作者：
HERZIG, RH
PHILLIPS, GL
LAZARUS, HM
WOLFF, SN
HERZIG, GP
机构：
[1] CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106
[2] WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63130
[3] VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37240
来源：
CANCER TREATMENT REPORTS | 1985年 / 69卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：881 / 883
页数：3
相关论文
共 50 条
  • [31] RANDOMIZED TRIAL OF HIGH-DOSE CYTARABINE VERSUS AMSACRINE IN ACUTE MYELOGENOUS LEUKEMIA IN RELAPSE - A LEUKEMIA INTERGROUP STUDY
    VOGLER, WR
    PREISLER, HD
    WINTON, EF
    GOTTLIEB, AJ
    GOLDBERG, J
    BRENNAN, J
    GRUNWALD, H
    RAI, K
    BROWMAN, G
    MILLER, KB
    CHERVENICK, P
    AZARNIA, N
    [J]. CANCER TREATMENT REPORTS, 1986, 70 (04): : 455 - 459
  • [32] Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone
    Bolaman, Z
    Köseoglu, M
    Ayyildiz, O
    Kadiköylü, G
    Sönmez, HM
    Demir, S
    Müftüoglu, E
    [J]. HAEMATOLOGIA, 2002, 32 (01) : 49 - 57
  • [33] Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia
    Stoklosa, Tomasz
    Glodkowska-Mrowka, Eliza
    Hoser, Grazyna
    Kielak, Magdalena
    Seferynska, Ilona
    Wlodarski, Pawel
    [J]. EXPERIMENTAL HEMATOLOGY, 2013, 41 (05) : 462 - 469
  • [34] DIFFERENTIAL ACTIVATION OF MTOR KINASE IN CHRONIC AND BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA
    Stoklosa, T.
    Glodkowska-Mrowka, E.
    Hoser, G.
    Seferynska, I.
    Wlodarski, P.
    [J]. HAEMATOLOGICA, 2013, 98 : 51 - 51
  • [35] Treatment of chronic myelogenous leukemia with high-dose recombinant interleukin-2: Results of a phase II study in 21 patients
    Vey, N
    Blaise, D
    Olive, D
    Lafage, M
    Viens, P
    Baume, D
    Camerlo, J
    Stoppa, AM
    Gabus, R
    Brandely, M
    Hercend, T
    Maraninchi, D
    [J]. EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 481 - 481
  • [36] Sudden onset of the blastic phase of chronic myelogenous leukemia - Patterns and implications
    Kantarjian, H
    O'Brien, S
    Cortes, J
    Giles, F
    Thomas, D
    Kornblau, S
    Shan, JQ
    Rios, MB
    Keating, M
    Freireich, E
    Talpaz, M
    [J]. CANCER, 2003, 98 (01) : 81 - 85
  • [37] INFECTION OF ELDERLY PATIENTS RECEIVING HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY FOR INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA (AML)
    NEMUNAITIS, J
    MEYER, W
    NEMUNAITIS, J
    TAYLOR, E
    RILEY, C
    COOPER, B
    [J]. LEUKEMIA RESEARCH, 1994, 18 (08) : 649 - 650
  • [38] TREATMENT OF ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA - PROSPECTIVE EVALUATION OF HIGH-DOSE CYTARABINE IN CONSOLIDATION CHEMOTHERAPY AND WITH BONE-MARROW TRANSPLANTATION
    CHAMPLIN, R
    HO, W
    WINSTON, D
    DECKER, R
    GREENBERG, P
    BURNISON, M
    HOLLY, FE
    GALE, RP
    [J]. SEMINARS IN ONCOLOGY, 1987, 14 (02) : 1 - 6
  • [39] PATIENT-SPECIFIC DOSE-RATE FOR CONTINUOUS INFUSION HIGH-DOSE CYTARABINE IN RELAPSED ACUTE MYELOGENOUS LEUKEMIA
    HEINEMANN, V
    ESTEY, E
    KEATING, MJ
    PLUNKETT, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (05) : 622 - 628
  • [40] HIGH-DOSE CYTOSINE-ARABINOSIDE - TREATMENT AND CELLULAR PHARMACOLOGY OF CHRONIC MYELOGENOUS LEUKEMIA BLAST CRISIS
    IACOBONI, SJ
    PLUNKETT, W
    KANTARJIAN, HM
    ESTEY, E
    KEATING, MJ
    MCCREDIE, KB
    FREIREICH, EJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (07) : 1079 - 1088
12345